Heterogeneity of prodromal Parkinson symptoms in siblings of Parkinson disease patients.
Journal
NPJ Parkinson's disease
ISSN: 2373-8057
Titre abrégé: NPJ Parkinsons Dis
Pays: United States
ID NLM: 101675390
Informations de publication
Date de publication:
07 Sep 2021
07 Sep 2021
Historique:
received:
06
03
2021
accepted:
09
07
2021
entrez:
8
9
2021
pubmed:
9
9
2021
medline:
9
9
2021
Statut:
epublish
Résumé
A prodromal phase of Parkinson's disease (PD) may precede motor manifestations by decades. PD patients' siblings are at higher risk for PD, but the prevalence and distribution of prodromal symptoms are unknown. The study objectives were (1) to assess motor and non-motor features estimating prodromal PD probability in PD siblings recruited within the European PROPAG-AGEING project; (2) to compare motor and non-motor symptoms to the well-established DeNoPa cohort. 340 PD siblings from three sites (Bologna, Seville, Kassel/Goettingen) underwent clinical and neurological evaluations of PD markers. The German part of the cohort was compared with German de novo PD patients (dnPDs) and healthy controls (CTRs) from DeNoPa. Fifteen (4.4%) siblings presented with subtle signs of motor impairment, with MDS-UPDRS-III scores not clinically different from CTRs. Symptoms of orthostatic hypotension were present in 47 siblings (13.8%), no different to CTRs (p = 0.072). No differences were found for olfaction and overall cognition; German-siblings performed worse than CTRs in visuospatial-executive and language tasks. 3/147 siblings had video-polysomnography-confirmed REM sleep behavior disorder (RBD), none was positive on the RBD Screening Questionnaire. 173/300 siblings had <1% probability of having prodromal PD; 100 between 1 and 10%, 26 siblings between 10 and 80%, one fulfilled the criteria for prodromal PD. According to the current analysis, we cannot confirm the increased risk of PD siblings for prodromal PD. Siblings showed a heterogeneous distribution of prodromal PD markers and probability. Additional parameters, including strong disease markers, should be investigated to verify if these results depend on validity and sensitivity of prodromal PD criteria, or if siblings' risk is not elevated.
Identifiants
pubmed: 34493736
doi: 10.1038/s41531-021-00219-1
pii: 10.1038/s41531-021-00219-1
pmc: PMC8423761
doi:
Types de publication
Journal Article
Langues
eng
Pagination
78Subventions
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Organisme : EC | Horizon 2020 Framework Programme (EU Framework Programme for Research and Innovation H2020)
ID : 634821
Investigateurs
Henry Houlden
(H)
Pietro Liò
(P)
Claudio Luchinat
(C)
Massimo Delledonne
(M)
Kevin Mills
(K)
Nancy L Pedersen
(NL)
Tiago Azevedo
(T)
Anna Bartoletti-Stella
(A)
Marta Bonilla-Toribio
(M)
Dolores Buiza-Rueda
(D)
Sabina Capellari
(S)
Mario Carriòn-Claro
(M)
Robert Clayton
(R)
Alessandra Dal Molin
(A)
Giovanna Maria Dimitri
(GM)
Ivan Doykov
(I)
Cristina Giuliani
(C)
Sara Hägg
(S)
Jenny Hällqvist
(J)
Wendy Heywood
(W)
Ismael Huertas
(I)
Juulia Jylhävä
(J)
Miguel A Labrador-Espinosa
(MA)
Cristina Licari
(C)
Daniel Macias
(D)
Francesca Magrinelli
(F)
Juan Francisco Martín Rodríguez
(JFM)
Maria Giovanna Maturo
(MG)
Giacomo Mengozzi
(G)
Gaia Meoni
(G)
Maddalena Milazzo
(M)
Christine Nardini
(C)
Nancy L Pedersen
(NL)
Maria Teresa Periñán-Tocino
(MT)
Francesco Ravaioli
(F)
Claudia Sala
(C)
Simeon Spasov
(S)
Cristina Tejera-Parrado
(C)
Leonardo Tenori
(L)
Turano Paola
(T)
Dylan Williams
(D)
Luciano Xumerle
(L)
Elisa Zago
(E)
Marcella Broli
(M)
Dolores Buiza-Rueda
(D)
Patrizia De Massis
(P)
Rocio Escuela-Martin
(R)
Giovanni Fabbri
(G)
Anna Gabellini
(A)
Pietro Guaraldi
(P)
Henry Houlden
(H)
Stefania Macrì
(S)
Stefania Alessandra Nassetti
(SA)
Cesa Lorella Maria Scaglione
(CLM)
Franco Valzania
(F)
Cilea Rosaria
(C)
Francesco Mignani
(F)
Rosario Vigo Ortega
(RV)
Claudia Boninsegna
(C)
Silvia De Luca
(S)
Informations de copyright
© 2021. The Author(s).
Références
Neurology. 2013 Oct 1;81(14):1226-34
pubmed: 23997153
JAMA Neurol. 2017 Dec 1;74(12):1431-1438
pubmed: 28973176
Mov Disord. 2015 Nov;30(13):1759-66
pubmed: 26179331
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Gastroenterology. 2006 Apr;130(5):1480-91
pubmed: 16678561
Eur J Neurol. 2019 Jul;26(7):979-985
pubmed: 30706593
Mov Disord. 2007 Dec;22(16):2386-93
pubmed: 17894337
Ann Neurol. 2008 Feb;63(2):167-73
pubmed: 18067173
Mech Ageing Dev. 2021 Mar;194:111426
pubmed: 33385396
J Neurol. 2020 Dec;267(12):3673-3682
pubmed: 32676768
Brain. 2012 Jun;135(Pt 6):1860-70
pubmed: 22561644
Neuroepidemiology. 2016;46(3):222-7
pubmed: 26967747
Home Healthc Now. 2016 Jun;34(6):300-7
pubmed: 27243427
PLoS One. 2016 Apr 15;11(4):e0152841
pubmed: 27082111
Neurology. 2020 Mar 17;94(11):481-494
pubmed: 32102975
Mov Disord. 2015 Apr;30(4):538-44
pubmed: 25600277
Arch Neurol. 1993 Feb;50(2):140-8
pubmed: 8431132
Laryngorhinootologie. 2014 May;93(5):327-9
pubmed: 24782205
Parkinsonism Relat Disord. 2012 Jan;18 Suppl 1:S199-202
pubmed: 22166434
Aging Cell. 2015 Jun;14(3):293-308
pubmed: 25677794
Neurology. 2019 May 7;92(19):e2261-e2272
pubmed: 30944240
Parkinsonism Relat Disord. 2019 Jul;64:275-279
pubmed: 31101555
Parkinsonism Relat Disord. 2019 Sep;66:74-79
pubmed: 31320275
Mov Disord Clin Pract. 2017 Dec 22;5(1):14-28
pubmed: 30363342
Lancet Neurol. 2019 Dec;18(12):1091-1102
pubmed: 31701892
J Neurol Sci. 2016 Dec 15;371:117-120
pubmed: 27871431
Parkinsonism Relat Disord. 2015 Dec;21(12):1421-6
pubmed: 26578041
Nat Rev Neurosci. 2017 Jul;18(7):435-450
pubmed: 28592904
Neurology. 2011 Sep 13;77(11):1048-54
pubmed: 21832215
Mov Disord. 2015 Apr 15;30(5):733-5
pubmed: 25737058
Mov Disord. 2017 Dec;32(12):1655-1666
pubmed: 28980730
Cell. 2015 Jan 29;160(3):570-570.e1
pubmed: 25635463
J Neurol Neurosurg Psychiatry. 2017 Mar;88(3):212-217
pubmed: 27986830
Mov Disord. 2017 May;32(5):789-793
pubmed: 28218413
Eur J Neurol. 2016 Nov;23(11):1606-1613
pubmed: 27444575
Mov Disord. 2015 Oct;30(12):1600-11
pubmed: 26474317
Ann Neurol. 2004 Oct;56(4):495-502
pubmed: 15455403
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
Eur J Neurol. 2014 May;21(5):766-72
pubmed: 24612314
Mov Disord. 2020 Oct;35(10):1802-1809
pubmed: 32567751
Mov Disord. 2016 Sep;31(9):1405-8
pubmed: 27273736
Arch Gen Psychiatry. 2007 Dec;64(12):1385-92
pubmed: 18056546
Mov Disord Clin Pract. 2016 Nov 01;4(3):403-405
pubmed: 30363451
Parkinsonism Relat Disord. 2018 Jul;52:62-68
pubmed: 29606605
Mov Disord. 2006 Jul;21(7):916-23
pubmed: 16547944
Mov Disord. 2018 Mar;33(3):405-413
pubmed: 29436728
Mov Disord. 2008 Jun 15;23(8):1174-83
pubmed: 18442112
Ann Neurol. 2012 Dec;72(6):893-901
pubmed: 23071076
Neurology. 2015 Jun 16;84(24):2422-9
pubmed: 25995056
Mov Disord Clin Pract. 2018 Mar 01;5(2):171-176
pubmed: 30009211
Eur J Neurol. 2013 Jan;20(1):102-8
pubmed: 22852790
Parkinsonism Relat Disord. 2020 Dec;81:213-218
pubmed: 33039276
Mov Disord. 2009 Apr 15;24(5):635-46
pubmed: 19205066
Mov Disord. 2017 Jul;32(7):1025-1034
pubmed: 28509336
Mov Disord. 2019 May;34(5):665-675
pubmed: 30919499
Mov Disord. 2019 Oct;34(10):1464-1470
pubmed: 31412427
Mov Disord. 2014 Dec;29(14):1796-801
pubmed: 25370724
NPJ Parkinsons Dis. 2018 Jul 10;4:21
pubmed: 30003140